The authors declare no competing interests.
DA: Designed the study, contributed to data collection, analysis, interpretation, and drafted the manuscript. AA: Contributed to data analysis, interpretation and drafting of the manuscript. KS: Contributed to data collection and interpretation. IA: Contributed to study design, data collection, interpretation and drafting of the manuscript. All authors read and approved of the manuscript.
DA is a certified Pediatric Endocrinologist who completed her paediatric residency at the Hospital for Sick children in Toronto, Ontario, Canada (RCPC). She then completed her pediatric training in Endocrinology and Metabolism at the Hospital for Sick Children in Toronto. Ontario, Canada (RCPC). She is currently an Assistant Professor at the Department of Pediatrics at the Faculty of Medicine, Kuwait University and a Pediatric Endocrinologist at the Department of Pediatrics at Mubarak Al-Kabeer Hospital, Kuwait.
Recombinant Growth hormone (rGH) therapy is approved in many countries for treatment of short stature in a number of childhood diagnoses. Despite the increasing body of international literature on rGH use, there is paucity of data on rGH use in Kuwait and the broader Middle-East which share unique ethnic and socio-cultural backgrounds. This study aimed to describe the pattern of use and treatment outcomes of rGH therapy in Kuwait.
This is a cross-sectional retrospective review of children treated with rGH in the Department of Pediatrics, in a major hospital in Kuwait between December 2013 and December 2014. Data were extracted using standard data extraction form and the response to rGH therapy was defined as a gain of ≥ 0.3 standard deviation score (SDS) of height per year.
A total of 60 children were treated with rGH in the center. Their Median (Interquartile) age at rGH initiation was 9.0 (6.2, 10.7) years. The most common indications for rGH therapy were Growth Hormone Deficiency (GHD) 23 (38.3 %), Idiopathic Short Stature (ISS) 12 (20.0 %) and Small for Gestational Age (SGA) 9 (15.0 %). After excluding patients with TS, no significant differences were found in gender of those who received rGH therapy in all indications combined or in each group (p ≥ 0.40). At 1-year follow-up, children in all groups had median height SDS change of ≥ 0.3 SDS except for children with ISS. Age at rGH initiation was negatively associated with 1-year treatment response, Adjusted odds ratio (AOR) 0.56 (95 % CI: 0.04–1.49); p = 0.011).
GHD is the most common indication of rGH therapy. All indications except for ISS showed significant 1-year treatment response to therapy. Treatment outcomes in patients with ISS should be further investigated in Kuwait. Younger age at initiation of rGH therapy was independently associated with significant response to therapy suggesting the importance of identifying children with short stature and prompt initiation of rGH therapy.
Lee PA, Sävendahl L, Oliver I, Tauber M, Blankenstein O, Ross J, et al. Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies. Int J Pediatr Endocrinol. 2012;2012(1):22. PubMedCentralCrossRefPubMed
Carel JC, Ecosse E, Nicolino M, Tauber M, Leger J, Cabrol S, et al. Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. BMJ. 2002;325(7355):70. PubMedCentralCrossRefPubMed
Bryant J, Djurhuus CB, Christensen T, Jøns K, Hokken-Koelega A. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev. 2007;3, CD004440. PubMed
Public Authority for Civil Information (PACI), Population Statistical Reports. 2014 [cited 2015 July 12th]; Available from: https://www.paci.gov.kw/Home.aspx.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93(11):4210–7. CrossRefPubMed
Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P; International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics. 2003;111(6 Pt 1):1253–61. CrossRefPubMed
Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92(3):804–10. CrossRefPubMed
Group, W.H.O.M.G.R.S. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl. 2006;450:76–85.
Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416–25. CrossRefPubMed
Grimberg A, Huerta-Saenz L, Grundmeier R, Ramos MJ, Pati S, Cucchiara AJ, et al. Gender Bias in U.S. Pediatric Growth Hormone Treatment. Sci Rep. 2015;5:11099.
Renes JS, Willemsen RH, Mulder JC, Bakker-van Waarde WM, Rotteveel J, Oostdijk W, et al. New insights into factors influencing adult height in short SGA children: Results of a large multicentre growth hormone trial. Clin Endocrinol (Oxf). 2015;82(6):854–61. CrossRef
Growth Hormone Research S. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990–3.
Rose SR, Shulman DI, Larsson P, Wakley LR, Wills S, Bakker B. Gender does not influence prepubertal growth velocity during standard growth hormone therapy--analysis of United States KIGS data. J Pediatr Endocrinol Metab. 2005;18(11):1045–51. PubMed
- Recombinant growth hormone therapy in children with short stature in Kuwait: a cross-sectional study of use and treatment outcomes
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II